Sinovac Life Sciences Co., Ltd.

This study tested a new 24-valent pneumococcal conjugate vaccine (PCV24) in 385 healthy adults aged 18 and older. The goal was to check its safety and how well it triggers an immune response compared to an existing vaccine. Participants received one dose of either a low, middle, …

This early-stage study tested a new oral rotavirus vaccine in 100 healthy people, from infants to adults. The main goal was to see if the vaccine is safe and well-tolerated. Researchers also checked how well the vaccine triggers an immune response in infants. The study was comple…

This early-stage trial tested a new 24-valent pneumococcal conjugate vaccine in 119 healthy children aged 2 to 17. The goal was to see if the vaccine is safe and helps the body build immunity against pneumococcal bacteria, which can cause pneumonia and other serious infections. R…

This early-phase study tested a new 13-valent pneumococcal conjugate vaccine in 310 healthy volunteers ranging from 6-week-old infants to adults up to 49 years old. The goal was to check the vaccine's safety and how well it triggers the immune system to fight pneumococcal bacteri…

This completed Phase 1/2 trial tested a new lab-made antibody called SNA02-48 for treating tetanus in 255 Chinese adults. The study compared SNA02-48 to the standard treatment (human tetanus immunoglobulin) to see if it is safe and how well it works. The goal is to find a more re…